Ellex 2RT® — Retinal Rejuvenation Therapy for early AMD

Ellex’s proprietary, patented laser therapy stimulates the eye's natural healing response to treat degenerative retinal diseases, including the early stages AMD. 

The first and Only Clinically Proven Laser Treatment to Delay Progression to Late-stage AMD

2RT™ — Retinal Rejuvenation Therapy — is Ellex’s proprietary, patented laser therapy that stimulates the eye's natural healing response to treat degenerative retinal diseases, including the early stages AMD. Ellex 2RT™ features proprietary Nanopix Technology™, which teams a nanosecond laser pulse with a unique pixelated beam profile to exclusively target selected individual cells within the retinal pigment epithelium.

2RT Highlights

 

  • Nanopix Technology
  • Earlier Intervention
  • No collateral Damage

Nanopix Technology™

Ellex 2RT® utilizes an ultra-short nanosecond laser pulse to target the compromised retinal pigment epithelium (RPE). A unique, proprietary pixelated beam profile ensures the selective targeting of nano-sized targets within the cellular structure of ageing RPE cells. With Nanopix Technology™ you can induce the orderly replacement of ageing RPE cells – without causing collateral damage to the overlying photoreceptor rods and cones of the retina.

The clinical application of Ellex’s Nanopix Technology™ is unique to Ellex 2RT® and cannot be extrapolated to other forms of retinal laser treatment, including subthreshold laser treatment.

AMD - Earlier Intervention

Ellex 2RT® offers the potential to intervene earlier in the disease process to improve retinal function and thereby slow the degenerative processes associated with AMD in its early stages. Clinical and scientific studies show that 2RT®  can induce a mononuclear cell response in the early intervention of AMD, including the stimulation of microglia.

CSME - Thermal Damage Avoided

Unlike conventional retinal photocoagulation, which can cause permanent damage to the eye's sensitive structures, 2RT™ uses 500 times less energy than retinal photocoagulation and eliminates the incidence of heat damage to the retina and surrounding cells in the effective treatment of Clinically Significant Macular Edema (CSME).3

3. Casson RJ. Et al., “Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema”, Clin Experiment Ophthalmol. 2012 Aug;40(6):604-10

Retinal Rejuvenation Therapy, 2RT®, stimulates a biological healing process that results in cellular rejuvenation, renewing the entire transport mechanism of the retina and improving the hydraulic conductivity of Bruch’s membrane. This rejuvenation process preserves or improves functional vision and reduces disease progression — without causing collateral damage to the overlying photoreceptor rods and cones of the retina. 2RT® offers the potential to intervene earlier in the treatment of AMD before significant vision loss has occurred to slow or halt the degeneration process.

The LEAD multi-center trial1 has shown that 2RT® Retinal Rejuvenation achieves a 77% reduction in the rate of progression to late stage AMD for over three quarters of early stage AMD patients, according to a post hoc analysis.

Learn more about 2RT Technology  

Testimonial

“While this isn’t a cure, and it is not suitable for every patient with AMD in its early stages, the impressive outcomes in reducing progression to late AMD are important as this is the first time that a laser intervention has shown promise in addressing AMD disease progression in more than 20 years of AMD laser research.”

Prof. Robyn Guymer AM, MBBS, PhD, FRANZCO, FAAHMS

2RT in Clinical Practice - Andrea Cusumano MD, PhD

Ellex sat down with Prof. Andrea Cusumano at the inaugural European Laser Innovations Forum in Nice to discuss the role of 2RT in clinical practice.

Play Video

Ellex 2RT Brochure

DOWNLOAD

2RT Results of LEAD Clinical Trial in Intermediate AMD

READ MORE

Rejuvenating Bruchs Membrane Whitepaper

READ MORE